Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Priority Review Weirdness: Tropical Voucher Sells For More; Owner Says It’s Worth Less

Executive Summary

Knight Therapeutics says a rare pediatric disease voucher is more valuable than its tropical disease voucher despite the sale price.

You may also be interested in...



Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher

Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.

Pricing, Pediatrics, Pot: 21st Century Cures Amendments

Committee members didn’t even vote on any amendments besides the manager’s package, but proposals floated and withdrawn offer glimpse at potential fights to come.

21st Century Cures Now A Partially Funded Mandate For FDA

Amended bill passes full House Energy and Commerce Committee unanimously with another $550 million in appropriations for FDA.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS056494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel